<p><img src="https://imageproxy.pbkrs.com/https://images.pexels.com/photos/5849595/pexels-photo-5849595.jpeg/query-YXV0bz1jb21wcmVzcyZjcz10aW55c3JnYiZkcHI9MSZ3PTUwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.pexels.com/photos/5849595/pexels-photo-5849595.jpeg/query-YXV0bz1jb21wcmVzcyZjcz10aW55c3JnYiZkcHI9MSZ3PTUwMA"/></p>
<p><em>图片来源：Pexels</em></p>
<p>虽然 “便宜股票” 没有确切的定义，因为这取决于个人偏好，但通常指的是每股交易价格在 5 到 10 美元之间的上市公司。便宜股票涵盖多个行业，提供了多样化投资组合的众多机会。</p>
<h3><strong>为什么要考虑投资便宜股票？</strong></h3>
<p>便宜股票可以为耐心的投资者提供令人兴奋的增长机会，前提是他们知道该寻找什么。它们还可以让投资者接触到尖端技术、医学、人工智能以及其他尚未取得突破但即将颠覆其行业的公司。</p>
<p>在评估便宜股票时，有几个事项需要考虑：</p>
<ul>
<li>投资于拥有成功管理团队的便宜股票，该团队有扭转公司局面的历史。</li>
<li>研究并了解行业，以及便宜股票如何通过其产品或服务产生显著影响。</li>
<li>仔细分析资产负债表，深入研究多个季度的财务报告，以确保便宜股票的债务较低，收入增长，并且有充足的现金储备。</li>
<li>始终为便宜股票保持一个单独的投资组合。</li>
</ul>
<h3><strong>便宜股票的缺点是什么？</strong></h3>
<p>投资者必须理解，便宜股票以低廉价格交易是有原因的，在投入资金之前，他们必须知道价格为何如此。可能存在财务问题、运营风险、法律麻烦以及其他投资者应当注意的问题。风险较高，流动性较低导致波动性仍然较大。</p>
<p>以下是当前值得考虑的便宜股票的简短列表：</p>
<ul>
<li>瑞穗金融集团 (MFG)</li>
<li>土耳其电信 (TKC)</li>
<li>CytomX 治疗 (CTMX)</li>
<li>Solid Power (SLDP)</li>
<li>Epsium 企业 (EPSM)</li>
<li>BigBear.ai 控股公司 (BBAI)</li>
<li>Magnitude International (MAGH)</li>
<li>Compass (COMP)</li>
<li>Navitas 半导体公司 (NVTS)</li>
<li>美国锑业公司 (UAMY)</li>
</ul>
<h3><strong>我之前推荐的最佳便宜股票更新</strong></h3>
<p>在我们之前的文章中，我强调了瑞穗金融集团和土耳其电信的上行潜力。</p>
<ul>
<li>瑞穗金融集团 - 在 6.48 美元到 6.75 美元之间建立了多头头寸。瑞穗最初下跌，然后上涨近 7%。此后股价回落至接近我的入场水平，我将继续持有我的多头头寸。</li>
<li>土耳其电信 - 在 5.35 美元到 5.62 美元之间建立了多头头寸。股价上涨超过 8% 后，随后又回落。该股票最近在我的入场区间内交易，我正在持有这一交易。</li>
</ul>
<h3><strong>CytomX 治疗的基本面分析</strong></h3>
<p>CytomX 治疗是一家临床阶段的生物制药公司，专注于通过更强效、毒性更低的抗癌药物来革新癌症治疗，主要产品为 Probody 治疗。</p>
<p>那么，在 CytomX 治疗的收益未达预期后，我为什么仍然看好它？</p>
<p>收入为 600 万美元，每股亏损 0.09 美元，未达到预期。尽管收入下降令人担忧，但我对其管线持乐观态度，CX-801 在晚期黑色素瘤患者中的第一阶段结果令人鼓舞，CX-2051 在晚期结直肠癌中的初步临床结果也很强劲。CX-2051 在其他晚期患者中也显示出潜力，包括肝转移和 KRAS 突变患者。</p>
<p><img src="https://imageproxy.pbkrs.com/https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144213401683.webp?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144213401683.webp"/></p>
<p><em>CytomX 治疗基本面分析快照</em></p>
<p>CytomX 治疗的市盈率为 12.82，使其成为一只便宜的股票。相比之下，标准普尔 500 指数的市盈率为 29.87。分析师对 CytomX 治疗的平均目标价为 7.07 美元。这表明具有良好的上行潜力和可接受的下行风险。</p>
<h3><strong>CytomX 治疗的技术分析</strong></h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.dailyforex.com/files/ctmx.webp?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.dailyforex.com/files/ctmx.webp"/></p>
<p><em>(点击图片放大)</em></p>
<p><em>CytomX 价格图表</em></p>
<p>该股票的 D1 图表显示 CytomX 的价格在其下降的 38.2% 和 50.0% 斐波那契回撤扇形之间的价格走势。它还显示该股票处于其水平支撑区间内。</p>
<p>此外，牛熊力量指标呈现看涨趋势，且趋势线向上。</p>
<h3><strong>我对 CytomX 治疗的看法</strong></h3>
<p>我在 CytomX 治疗股票的价格区间为 3.49 美元到 3.93 美元之间建立了多头头寸。尽管价格低于 5.00 美元，但它具有巨大的上行潜力，现金余额健康，没有立即的运营问题，并且管线前景良好。</p>
<h3><strong>Solid Power 基本面分析</strong></h3>
<p>Solid Power 开发下一代全固态电池技术。除了开发全固态电池单元技术外，它还向其他活跃于固态领域的公司销售硫化物固体电解质。</p>
<p>那么，在 Solid Power 的收益报告后，我为什么仍然看好它？</p>
<p>截至目前的收入为 1810 万美元，比去年增加 240 万美元。运营费用在减少，其资本状况保持良好，这得益于其市场发行和政府合同。在 Solid Power 与三星 SDI 和宝马达成有前景的合同后，我转为看好，确认了其全固态电池单元技术在工业应用中的信心。</p>
<p><img src="https://imageproxy.pbkrs.com/https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144882942547.webp?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144882942547.webp"/></p>
<p><em>Solid Power 基本面分析快照</em></p>
<p>Solid Power 股票的市盈率数据不可用。该股票的平均分析师目标价为 7.00 美元。这表明具有良好的上行潜力和降低的下行风险。</p>
<h3><strong>Solid Power 技术分析</strong></h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.dailyforex.com/files/sldp.webp?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.dailyforex.com/files/sldp.webp"/></p>
<p><em>(点击图片放大)</em></p>
<p><em>Solid Power 价格图表</em></p>
<p>D1 图表显示 Solid Power 的价格走势低于其上升的斐波那契回撤扇形，同时也显示该股票接近其水平支撑区。</p>
<p>此外，牛熊力量指标呈现看跌趋势，但一条上升趋势线已经开始形成。</p>
<h3><strong>我对 Solid Power 的看法</strong></h3>
<p>我将在 Solid Power 股票的价格区间为 4.32 美元至 4.77 美元之间建立多头头寸。尽管 Solid Power 的运营指标令人担忧，但其业务正在朝着正确的方向发展。其资本状况依然优秀，与三星 SDI 和宝马的近期合作预计将在未来几个季度提供显著的看涨催化剂。</p>
<hr/>
<p><em>更多来自此作者的文章：</em></p>
<p>Fastenal 股票信号：您应该为您的投资组合加固吗？</p>
<p>值得购买的最佳核能股票</p>
<p>现在值得购买的最佳黄金股票</p>

瑞穗金融集团

CytomX治疗

<p>这篇文章讨论了投资于便宜股票的潜力，这些股票通常每股价格在 5 到 10 美元之间，涵盖多个行业。文章强调了此类投资的增长机会和风险。文章提供了一份值得考虑的便宜股票的简短名单，包括瑞穗金融集团、土耳其电信公司、CytomX 治疗和 Solid Power。它对 CytomX 治疗和 Solid Power 进行了基本面和技术分析，强调了它们有前景的产品线和财务状况</p>

<p><img src="https://imageproxy.pbkrs.com/https://images.pexels.com/photos/5849595/pexels-photo-5849595.jpeg/query-YXV0bz1jb21wcmVzcyZjcz10aW55c3JnYiZkcHI9MSZ3PTUwMA" alt="" original-src="https://images.pexels.com/photos/5849595/pexels-photo-5849595.jpeg?auto=compress&amp;cs=tinysrgb&amp;dpr=1&amp;w=500"/></p>
<p><em>Image Source: Pexels</em></p>
<div class="lb-trans"><p><em>图片来源：Pexels</em></p>
</div><p>While there is no exact definition of “cheap stocks,” as it depends on individual preferences, they typically refer to listed companies that trade between $5 and $10 per share. Cheap stocks are available across various sectors and offer numerous opportunities to diversify portfolios.</p>
<div class="lb-trans"><p>虽然 “便宜股票” 没有确切的定义，因为这取决于个人偏好，但通常指的是每股交易价格在 5 到 10 美元之间的上市公司。便宜股票涵盖多个行业，提供了多样化投资组合的众多机会。</p>
</div><h3><strong>Why Should You Consider Investing in Cheap Stocks?</strong></h3>
<div class="lb-trans"><h3><strong>为什么要考虑投资便宜股票？</strong></h3>
</div><p>Cheap stocks can offer exciting growth opportunities for patient investors who know what to look for. They can also provide exposure to cutting-edge technology, medicine, AI, and other companies that have not yet achieved a breakthrough but are on the verge of disrupting their industries.</p>
<div class="lb-trans"><p>便宜股票可以为耐心的投资者提供令人兴奋的增长机会，前提是他们知道该寻找什么。它们还可以让投资者接触到尖端技术、医学、人工智能以及其他尚未取得突破但即将颠覆其行业的公司。</p>
</div><p>Here are a few things to consider when evaluating cheap stocks:</p>
<div class="lb-trans"><p>在评估便宜股票时，有几个事项需要考虑：</p>
</div><ul>
<li>Invest in cheap stocks with a proven management team that has a history of turning around companies.</li>
<li>Research and understand the industry and how a cheap stock can make a notable impact with their product or service.</li>
<li>Analyze the balance sheet carefully and dig through several quarters of financial reports to ensure the cheap stock is low on debt, has growing revenues, and plenty of cash reserves.</li>
<li>Always keep a separate portfolio for cheap stocks.</li>
</ul>
<div class="lb-trans"><ul>
<li>投资于拥有成功管理团队的便宜股票，该团队有扭转公司局面的历史。</li>
<li>研究并了解行业，以及便宜股票如何通过其产品或服务产生显著影响。</li>
<li>仔细分析资产负债表，深入研究多个季度的财务报告，以确保便宜股票的债务较低，收入增长，并且有充足的现金储备。</li>
<li>始终为便宜股票保持一个单独的投资组合。</li>
</ul>
</div><h3><strong>What are the Downsides of Cheap Stocks?</strong></h3>
<div class="lb-trans"><h3><strong>便宜股票的缺点是什么？</strong></h3>
</div><p>Investors must understand that cheap stocks trade at bargain prices for a reason, and before they commit capital, they must know why the price is where it is. There could be financial issues, operational risks, legal troubles, and other problems that investors should be aware of. The risk is higher, and volatility remains elevated due to less liquidity.</p>
<div class="lb-trans"><p>投资者必须理解，便宜股票以低廉价格交易是有原因的，在投入资金之前，他们必须知道价格为何如此。可能存在财务问题、运营风险、法律麻烦以及其他投资者应当注意的问题。风险较高，流动性较低导致波动性仍然较大。</p>
</div><p>Here is a shortlist of cheap stocks currently worth considering:</p>
<div class="lb-trans"><p>以下是当前值得考虑的便宜股票的简短列表：</p>
</div><ul>
<li>Mizuho Financial Group (MFG)</li>
<li>Turkcell Iletisim Hizmetleri (TKC)</li>
<li>CytomX Therapeutics (CTMX)</li>
<li>Solid Power (SLDP)</li>
<li>Epsium Enterprise (EPSM)</li>
<li>BigBear.ai Holdings, Inc. (BBAI)</li>
<li>Magnitude International (MAGH)</li>
<li>Compass (COMP)</li>
<li>Navitas Semiconductor Corporation (NVTS)</li>
<li>United States Antimony Corporation (UAMY)</li>
</ul>
<div class="lb-trans"><ul>
<li>瑞穗金融集团 (MFG)</li>
<li>土耳其电信 (TKC)</li>
<li>CytomX 治疗 (CTMX)</li>
<li>Solid Power (SLDP)</li>
<li>Epsium 企业 (EPSM)</li>
<li>BigBear.ai 控股公司 (BBAI)</li>
<li>Magnitude International (MAGH)</li>
<li>Compass (COMP)</li>
<li>Navitas 半导体公司 (NVTS)</li>
<li>美国锑业公司 (UAMY)</li>
</ul>
</div><h3><strong>Update on My Previous List of Best Cheap Stocks to Buy Now</strong></h3>
<div class="lb-trans"><h3><strong>我之前推荐的最佳便宜股票更新</strong></h3>
</div><p>In our previous installment, I highlighted the upside potential of Mizuho Financial Group and Turkcell Iletisim Hizmetleri.</p>
<div class="lb-trans"><p>在我们之前的文章中，我强调了瑞穗金融集团和土耳其电信的上行潜力。</p>
</div><ul>
<li>Mizuho Financial Group - A long position was taken in the stock between $6.48 and $6.75. Mizuho initially moved lower before advancing almost 7%. It has since retreated close to my entry level, and I will continue holding my long position.</li>
<li>Turkcell Iletisim Hizmetleri - A long position was taken in the stock between $5.35 and $5.62. After rising by over 8%, shares rallied and then dropped again. The stock has recently been trading inside my entry zone, and I am holding this trade.</li>
</ul>
<div class="lb-trans"><ul>
<li>瑞穗金融集团 - 在 6.48 美元到 6.75 美元之间建立了多头头寸。瑞穗最初下跌，然后上涨近 7%。此后股价回落至接近我的入场水平，我将继续持有我的多头头寸。</li>
<li>土耳其电信 - 在 5.35 美元到 5.62 美元之间建立了多头头寸。股价上涨超过 8% 后，随后又回落。该股票最近在我的入场区间内交易，我正在持有这一交易。</li>
</ul>
</div><h3><strong>CytomX Therapeutics Fundamental Analysis</strong></h3>
<div class="lb-trans"><h3><strong>CytomX 治疗的基本面分析</strong></h3>
</div><p>CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on revolutionizing cancer treatments with more potent, less toxic anti-cancer medications, led by its Probody therapeutics product.</p>
<div class="lb-trans"><p>CytomX 治疗是一家临床阶段的生物制药公司，专注于通过更强效、毒性更低的抗癌药物来革新癌症治疗，主要产品为 Probody 治疗。</p>
</div><p>So, why am I bullish on CytomX Therapeutics after its earnings miss?</p>
<div class="lb-trans"><p>那么，在 CytomX 治疗的收益未达预期后，我为什么仍然看好它？</p>
</div><p>Revenues of $6.0 million and an earnings per share loss of $0.09 per share missed estimates. While the drop in revenues was a concern, I am bullish about its pipeline, with promising Phase 1 results for CX-801 in advanced melanoma patients and robust initial clinical results for CX-2051 in late-line colorectal cancer. CX 2051 also shows potential in other late-stage patients, including those with liver metastases and KRAS mutations.</p>
<div class="lb-trans"><p>收入为 600 万美元，每股亏损 0.09 美元，未达到预期。尽管收入下降令人担忧，但我对其管线持乐观态度，CX-801 在晚期黑色素瘤患者中的第一阶段结果令人鼓舞，CX-2051 在晚期结直肠癌中的初步临床结果也很强劲。CX-2051 在其他晚期患者中也显示出潜力，包括肝转移和 KRAS 突变患者。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144213401683.webp" alt="" original-src="https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144213401683.webp"/></p>
<p><em>CytomX Therapeutics Fundamental Analysis Snapshot</em></p>
<div class="lb-trans"><p><em>CytomX 治疗基本面分析快照</em></p>
</div><p>The price-to-earnings (P/E) ratio of 12.82 makes CytomX Therapeutics an inexpensive stock. By comparison, the P/E ratio for the S&amp;P 500 Index is 29.87. The average analyst price target for CytomX Therapeutics is $7.07. This suggests excellent upside potential with acceptable downside risks.</p>
<div class="lb-trans"><p>CytomX 治疗的市盈率为 12.82，使其成为一只便宜的股票。相比之下，标准普尔 500 指数的市盈率为 29.87。分析师对 CytomX 治疗的平均目标价为 7.07 美元。这表明具有良好的上行潜力和可接受的下行风险。</p>
</div><h3><strong>CytomX Therapeutics Technical Analysis</strong></h3>
<div class="lb-trans"><h3><strong>CytomX 治疗的技术分析</strong></h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.dailyforex.com/files/ctmx.webp" alt="" original-src="https://www.dailyforex.com/files/ctmx.webp"/></p>
<p><em>(Click on image to enlarge)</em></p>
<div class="lb-trans"><p><em>(点击图片放大)</em></p>
</div><p><em>CytomX price chart</em></p>
<div class="lb-trans"><p><em>CytomX 价格图表</em></p>
</div><p>The stock D1 chart shows CytomX's price action between its descending 38.2% and 50.0% Fibonacci Retracement Fan. It also shows the stock inside its horizontal support zone.</p>
<div class="lb-trans"><p>该股票的 D1 图表显示 CytomX 的价格在其下降的 38.2% 和 50.0% 斐波那契回撤扇形之间的价格走势。它还显示该股票处于其水平支撑区间内。</p>
</div><p>Additionally, the Bull Bear Power Indicator is bullish with an ascending trendline.</p>
<div class="lb-trans"><p>此外，牛熊力量指标呈现看涨趋势，且趋势线向上。</p>
</div><h3><strong>My Call on CytomX Therapeutics</strong></h3>
<div class="lb-trans"><h3><strong>我对 CytomX 治疗的看法</strong></h3>
</div><p>I am taking a long position in CytomX Therapeutics stock between $3.49 and $3.93. While the price is below $5.00, it has tremendous upside potential, with a healthy cash balance, no immediate operational concerns, and a promising pipeline.</p>
<div class="lb-trans"><p>我在 CytomX 治疗股票的价格区间为 3.49 美元到 3.93 美元之间建立了多头头寸。尽管价格低于 5.00 美元，但它具有巨大的上行潜力，现金余额健康，没有立即的运营问题，并且管线前景良好。</p>
</div><h3><strong>Solid Power Fundamental Analysis</strong></h3>
<div class="lb-trans"><h3><strong>Solid Power 基本面分析</strong></h3>
</div><p>Solid Power develops next-generation all-solid-state battery technology. Besides developing all-solid-state battery cell technology, it also sells sulfide solid electrolytes to other companies active in the solid-state sectors.</p>
<div class="lb-trans"><p>Solid Power 开发下一代全固态电池技术。除了开发全固态电池单元技术外，它还向其他活跃于固态领域的公司销售硫化物固体电解质。</p>
</div><p>So, why am I bullish on Solid Power after its earnings report?</p>
<div class="lb-trans"><p>那么，在 Solid Power 的收益报告后，我为什么仍然看好它？</p>
</div><p>Year-to-date revenues came in at $18.1 million, up $2.4 million versus last year. Operating expenses are decreasing, and its capital position remains excellent, thanks to its at-the-market offering and government contracts. I turned bullish after Solid Power secured promising contracts with Samsung SDI and BMW, confirming confidence in its industrial application for its all-solid-state battery cell technology.</p>
<div class="lb-trans"><p>截至目前的收入为 1810 万美元，比去年增加 240 万美元。运营费用在减少，其资本状况保持良好，这得益于其市场发行和政府合同。在 Solid Power 与三星 SDI 和宝马达成有前景的合同后，我转为看好，确认了其全固态电池单元技术在工业应用中的信心。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144882942547.webp" alt="" original-src="https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144882942547.webp"/></p>
<p><em>Solid Power Fundamental Analysis Snapshot</em></p>
<div class="lb-trans"><p><em>Solid Power 基本面分析快照</em></p>
</div><p>The price-to-earnings (P/E) data for Solid Power stock is unavailable. The average analyst price target for the stock is $7.00. This suggests excellent upside potential with decreasing downside risks.</p>
<div class="lb-trans"><p>Solid Power 股票的市盈率数据不可用。该股票的平均分析师目标价为 7.00 美元。这表明具有良好的上行潜力和降低的下行风险。</p>
</div><h3><strong>Solid Power Technical Analysis</strong></h3>
<div class="lb-trans"><h3><strong>Solid Power 技术分析</strong></h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.dailyforex.com/files/sldp.webp" alt="" original-src="https://www.dailyforex.com/files/sldp.webp"/></p>
<p><em>(Click on image to enlarge)</em></p>
<div class="lb-trans"><p><em>(点击图片放大)</em></p>
</div><p><em>Solid Power Price Chart</em></p>
<div class="lb-trans"><p><em>Solid Power 价格图表</em></p>
</div><p>The stock D1 chart shows Solid Power's price action trading below its ascending Fibonacci Retracement Fan. It also shows the stock approaching its horizontal support zone.</p>
<div class="lb-trans"><p>D1 图表显示 Solid Power 的价格走势低于其上升的斐波那契回撤扇形，同时也显示该股票接近其水平支撑区。</p>
</div><p>Additionally, the Bull Bear Power Indicator is bearish, but an ascending trendline has begun to form.</p>
<div class="lb-trans"><p>此外，牛熊力量指标呈现看跌趋势，但一条上升趋势线已经开始形成。</p>
</div><h3><strong>My Call on Solid Power</strong></h3>
<div class="lb-trans"><h3><strong>我对 Solid Power 的看法</strong></h3>
</div><p>I am taking a long position in Solid Power stock between $4.32 and $4.77. While Solid Power has troubling operational metrics, its business is moving in the right direction. Its capital position remains excellent, and recent partnerships with Samsung SDI and BMW should provide a significant bullish catalyst in the quarters to come.</p>
<div class="lb-trans"><p>我将在 Solid Power 股票的价格区间为 4.32 美元至 4.77 美元之间建立多头头寸。尽管 Solid Power 的运营指标令人担忧，但其业务正在朝着正确的方向发展。其资本状况依然优秀，与三星 SDI 和宝马的近期合作预计将在未来几个季度提供显著的看涨催化剂。</p>
</div><hr/>
<div class="lb-trans"><hr/>
</div><p><em>More By This Author:</em></p>
<div class="lb-trans"><p><em>更多来自此作者的文章：</em></p>
</div><p>Fastenal Stock Signal: Should You Fasten Your Portfolio?</p>
<div class="lb-trans"><p>Fastenal 股票信号：您应该为您的投资组合加固吗？</p>
</div><p>The Best Nuclear Energy Stocks To Buy</p>
<div class="lb-trans"><p>值得购买的最佳核能股票</p>
</div><p>The Best Gold Stocks To Buy Now</p>
<div class="lb-trans"><p>现在值得购买的最佳黄金股票</p>
</div>

当前最值得购买的廉价股票